The invention discloses two kinds of shRNA interfering with human IL 6 6 gene expression, such as SEQ ID NO:1 and 2. The present invention also discloses a lentivirus expression vector which contains shRNA interfering with the expression of human IL 6 gene and nucleotide fragments encoding chimeric antigen receptors as shown in SEQ ID NO:4. The present invention also discloses a CD19 CAR T cell interfering with the expression of human IL_6 gene, which is a T lymphocyte containing a lentivirus expression vector, or a T lymphocyte integrating shRNA interfering with the expression of human IL_6 gene in chromosome, and a nucleotide fragment encoding a chimeric antigen receptor. The CAR T cells of the present invention introduce IL 6 shRNA, co-express IL 6 shRNA while expressing CAR, and inhibit the release of IL 6 from the source by gene silencing technology, thereby reducing the impact of CRS and improving the safety of CAR T treatment. It can be predicted that there will be important applications in the preparation of drugs for the prevention, treatment and adjuvant treatment of malignant tumors.
【技术实现步骤摘要】
干扰IL-6表达的CD19-CAR-T细胞及其应用
本专利技术涉及干扰IL-6表达的靶向CD19的嵌合抗原受体T细胞(ChimericAntigenReceptorTcell,CAR-T)的制备及其应用,属于基因工程和细胞生物学领域。
技术介绍
1989年,嵌合抗原受体改造T细胞(CAR-T)这一概念被首次提出,目的是建立肿瘤特异性识别能力的过继细胞疗法。第一代CAR的设计是简单的用特异性单克隆抗体来源的scFv(single-chainantibodyvariableregionfragment)段替换TCR(Tcellreceptor)的胞外区部分,保留了跨膜结构和胞内传递信号的CD3ζ区域,有的研究组胞内信号传递部分也会采用FcR。但第一代CAR的临床试验结果却非常令人失望,效果最好的一次临床试验也仅仅有2/11个病人有长期的缓解。随着对免疫学认识的不断深入,人们发现CD3ζ信号虽然能够诱导T细胞的活化和短暂增殖,但之后会诱导T细胞的无能(anergy)。1998年,有两个实验室报道了CD28信号结构域可以为CD3ζ信号提供辅助的共刺激功能。因此,第二代CAR的设计在第一代的基础上引入了共刺激分子的部分,如CD28或CD137(4-1BB)的胞内信号结构域。而第三代CAR则是加入了2个共刺激分子的功能信号结构域,包括CD27、CD28、4-1BB、ICOS或OX40(15-18)。现在在临床上进行实验的主要是第二代CAR的设计。CAR-T的疗效已经被业内所公认,2017年8月30日,美国FDA批准了首个CAR-T药物——Kymriah(tisagen ...
【技术保护点】
1.干扰人IL‑6基因表达的shRNA,其特征在于:为IL‑6 shRNA‑1,或IL‑6 shRNA‑2,IL‑6 shRNA‑1的核苷酸序列如下所示,IL‑6 shRNA‑2的核苷酸序列如下所示:IL‑6 shRNA‑1,如SEQ ID NO:1所示:GCGGCCGCCCTGGATTCAATGAGGAGACTTTTCAAGAGAAAGTCTCCTCATTGAATCCAGTTTT;IL‑6 shRNA‑2,如SEQ ID NO:2所示:GCGGCCGCCCAGAACGAATTGACAAACAAATTCAAGAGATTTGTTTGTCAATTCGTTCTGTTTTT。
【技术特征摘要】
1.干扰人IL-6基因表达的shRNA,其特征在于:为IL-6shRNA-1,或IL-6shRNA-2,IL-6shRNA-1的核苷酸序列如下所示,IL-6shRNA-2的核苷酸序列如下所示:IL-6shRNA-1,如SEQIDNO:1所示:GCGGCCGCCCTGGATTCAATGAGGAGACTTTTCAAGAGAAAGTCTCCTCATTGAATCCAGTTTT;IL-6shRNA-2,如SEQIDNO:2所示:GCGGCCGCCCAGAACGAATTGACAAACAAATTCAAGAGATTTGTTTGTCAATTCGTTCTGTTTTT。2.用于制备权利要求1所述的干扰人IL-6基因表达的shRNA的引物,其特征在于:用于制备IL-6shRNA-1的引物,其核苷酸序列如下所示:hIL-6-shRNA1-1st:GGCCGCCCTGGATTCAATGAGGAGACTTTTCAAGAGA;hIL-6-shRNA1-2nd:AAGTCTCCTCATTGAATCCAGTTTTTGC;hIL-6-shRNA1-3rd:AAGTCTCCTCATTGAATCCAGGGC;hIL-6-shRNA1-4th:GGCCGCAAAAACTGGATTCAATGAGGAGACTTTCTCTTGAA;用于制备上IL-6shRNA-2的引物,其核苷酸序列如下所示:hIL-6-shRNA2-1st:GGCCGCCCAGAACGAATTGACAAACAAATTCAAGAGA;hIL-6-shRNA2-2nd:TTTGTTTGTCAATTCGTTCTGTTTTTGC;hIL-6-shRNA2-3rd:TTTGTTTGTCAATTCGTTCTGGGC;hIL-6-shRNA2-4th:GGCCGCAAAAACAGAACGAATT...
【专利技术属性】
技术研发人员:谭毅,郭红,张慧慧,
申请(专利权)人:山东省齐鲁细胞治疗工程技术有限公司,
类型:发明
国别省市:山东,37
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。